Drug intelligence / Profile preview

SKB264 + inetetamab

Development stage: Unknown
Lead developer: Kelun-Biotech
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SKB264 + inetetamab is an investigational combination therapy comprising the TROP2-directed antibody-drug conjugate (ADC) SKB264 (also known as sacituzumab tirumotecan or MK-2870) and the anti-HER2 monoclonal antibody inetetamab (Cipterbin). SKB264 consists of a humanized anti-TROP2 antibody conjugated to a belotecan-derivative topoisomerase I inhibitor payload (KL610023) via a pH-sensitive linker, allowing for targeted delivery and release within the tumor microenvironment. Inetetamab is a recombinant humanized monoclonal antibody targeting HER2, engineered with a modified Fc region to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) compared to standard trastuzumab. This combination is being evaluated in the Phase II SHINE-HER trial for patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who have progressed following treatment with trastuzumab deruxtecan (T-DXd).

Brand names: Cipterbin
Other names: sacituzumab tirumotecan + inetetamabMK-2870 + inetetamabSKB264 + Cipterbin

Targets

TACSTD2 (Tumor-associated calcium signal transducer 2)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on SKB264 + inetetamab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKB264 + inetetamab.

Explore the full profile